Korro Bio, INC Form 4 insider transactions

Director Nessan Bermingham acquired 5,190 stock options in Korro Bio, Inc. on June 11, 2024.

Director Timothy R. Pearson acquired stock options in Korro Bio, Inc. on June 11, 2024.

Director David L. Lucchino acquired stock options in Korro Bio, Inc. on June 11, 2024.

Olukemi Olugemo, Chief Medical Officer of Korro Bio, Inc., acquired 65,000 stock options on June 3, 2024, at an exercise price of $50.48.

New Enterprise Associates 17, L.P. acquired 17,857 shares of Korro Bio, Inc. common stock at $56 per share on April 22, 2024, and indirectly holds 1,090,793 shares.

Forest Baskett, a director at Korro Bio, acquired 17,857 shares of common stock on April 22, 2024, through a subscription agreement.

Ali Behbahani, a director and 10% owner of Korro Bio, Inc., reports acquiring 17,857 shares of common stock at $56 per share on April 22, 2024.

Anthony A. Florence, Jr., a director at Korro Bio, Inc., acquired 17,857 shares of common stock at $56 per share on April 22, 2024.

Paul Edward Walker, a director of Korro Bio, Inc., indirectly acquired 17,857 shares of common stock at $56 per share on April 22, 2024, through a transaction related to a Subscription Agreement.

Carmen Chang, a director of Korro Bio, indirectly acquired 17,857 shares of common stock at $56 per share on April 22, 2024, through NEA 17.

Edward Mathers, a director of Korro Bio, Inc., acquired 17,857 shares of common stock at $56 per share on April 22, 2024, pursuant to a subscription agreement.

Rick Yang, a director at Korro Bio, acquired 17,857 shares of common stock at $56 per share on April 22, 2024, through a subscription agreement.

Mohamad Makhzoumi, a director indirectly associated with NEA 17, acquired 17,857 shares of Korro Bio, Inc. common stock at $56 per share on April 22, 2024.

Scott Sandell, a director of Korro Bio, acquired 17,857 shares of common stock at $56 per share on April 22, 2024, through a subscription agreement.

Director Jean Francois Formela reports acquisition of 17,857 shares of Korro Bio, Inc. common stock at $56 per share on April 22, 2024.

Atlas Venture Opportunity Fund II, L.P. reports a disposition of Korro Bio, Inc. shares, decreasing its holdings.